A look at the shareholders of Kindstar Globalgene Technology, Inc. (HKG:9960) can tell us which group is the most powerful. With a 53% stake, individual investors own the maximum number of shares in the company. In other words, the group stands to gain more (or lose more) from its investment in the company.
And last week, individual investors suffered the biggest losses, as shares fell 11%.
Let’s take a closer look to see what different types of shareholders can tell us about Kindstar Globalgene Technology.
However, if you prefer to see where the opportunities and risks are within the 9960 industryyou can check out our analysis on the HK Healthcare industry.
What does institutional ownership tell us about Kindstar Globalgene technology?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. Therefore, they generally consider buying larger companies that are included in the relevant benchmark.
As you can see, institutional investors have a sizeable stake in Kindstar Globalgene Technology. This may indicate that the company has some degree of credibility in the investment community. However, it is best to be careful about trusting the so-called validation that comes with institutional investors. They also make mistakes sometimes. If multiple institutions change their opinion on a stock at the same time, the share price may drop rapidly. So it’s worth looking at Kindstar Globalgene Technology’s earnings history below. Of course, the future is what really matters.
Kindstar Globalgene Technology is not owned by hedge funds. The company’s largest shareholder is UBS Asset Management, with a 0.1% stake. Meanwhile, the second largest shareholder is ABN AMRO Investment Solutions with 0.05%.
A deeper look at our ownership data shows that the top 2 shareholders collectively own less than half of the record, suggesting a large group of small owners where no single shareholder has a majority.
Researching institutional ownership is a good way to measure and filter the expected return of a stock. The same can be achieved by studying the sentiments of analysts. There are a reasonable number of analysts covering the stock, so it might be helpful to know their aggregate view on the future.
Internally owned by Kindstar Globalgene Technology
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company’s management runs the business, but the CEO will answer to the board, even if he is a member of it.
In general, I find internal ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
Our information suggests that the experts hold a significant stake in Kindstar Globalgene Technology, Inc. The experts have a HK$250 million stake in this HK$1.9 billion business. It’s great to see the experts so involved in the business. It might be worth checking to see if those experts have been buying recently.
General public property
The general public, made up mostly of individual investors, collectively owns 53% of the shares of Kindstar Globalgene Technology. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions about executive compensation, dividend policies, and proposed business acquisitions.
Private equity ownership
Private equity firms have a 17% stake in Kindstar Globalgene Technology. This suggests that they can influence key political decisions. This could discourage some investors, as private equity can sometimes encourage strategies that help the market see the value of the company. Alternatively, those holders could exit the investment after going public.
Private company ownership
Our data indicates that Private Companies own 4.9% of the company’s shares. It is difficult to draw conclusions from this fact alone, so it is worth investigating who owns such private companies. Sometimes, insiders or other related parties have an interest in shares of a public company through a separate private company.
It is always worth thinking about the different groups that own shares in a company. But to better understand Kindstar Globalgene technology, we must consider many other factors. Please note that Kindstar Globalgene Technology is displaying 2 warning signs in our investment analysis and 1 of those is a bit nasty…
But lately it is the future, not the past, that will determine how well the owners of this business will do. Therefore, we think it is advisable to take a look at this free report that shows if the analysts predict a better future.
Note: The figures in this article are calculated using data from the last twelve months, which refers to the 12-month period ending on the last day of the month in which the financial statement is dated. This may not be consistent with the annual report figures for the full year.
Do you have comments about this article? Concerned about the content? Get in touch with us directly. Alternatively, email the editorial team (at) Simplywallst.com.
This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodology and our articles are not intended to be financial advice. It is not a recommendation to buy or sell any stock, and it does not take into account your goals or financial situation. Our goal is to provide you with long-term focused analysis driven by fundamental data. Please note that our analysis may not take into account the latest announcements from price-sensitive companies or qualitative material. Simply Wall St has no position in any of the stocks mentioned.
Titration is complex, but we’re helping to simplify it.
find out if Kindstar Globalgene Technology is potentially overvalued or undervalued by consulting our comprehensive analysis, which includes fair value estimates, risks and caveats, dividends, internal transactions and financial health.
See the free analysis